The current status and prospects of gut microbiota combined with PD-1/PD-L1 inhibitors in the treatment of colorectal cancer: a review
Abstract Background Colorectal cancer (CRC) is a common malignant tumor. Immune checkpoint inhibitors (ICIs), particularly those targeting programmed cell death protein 1(PD-1) and programmed cell death ligand 1(PD-L1), have shown promising potential in the treatment of CRC. Specific gut microbiota...
Saved in:
| Main Authors: | Min Deng, Xiaoyu Li, Huiming Wu, Dingwen Xue, Yize Wang, Renkai Guo, Yipeng Cui, Chenfei Jin, Fei luo, Huiyu Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-025-03968-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Potential of PD-1 and PD-L1 as Prognostic and Predictive Biomarkers in Colorectal Adenocarcinoma Based on TILs Grading
by: Nur Rahmah Rasyid, et al.
Published: (2024-11-01) -
Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials
by: Zhenzi Wang, et al.
Published: (2024-12-01) -
Perspectives of Targeting Autophagy as an Adjuvant to Anti-PD-1/PD-L1 Therapy for Colorectal Cancer Treatment
by: Nasrah ALKhemeiri, et al.
Published: (2025-05-01) -
ROLE OF PD-L1 ASSESSMENT IN THE ASPECT OF MOLECULAR-GENETIC CLASSIFICATION OF COLORECTAL CANCER. CURRENT STATE OF THE PROBLEM
by: S. V. Vtorushin, et al.
Published: (2021-03-01) -
High-dose Vitamin C inhibits PD-L1 expression by activating AMPK in colorectal cancer
by: Jia Huang, et al.
Published: (2025-05-01)